Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TAK-505

Bispecific antibody · Immune activation, directed at programmed death-ligand 1 (CD274) and gamma-delta T-cell receptor Vdelta1 segment (TRDV1) · developed by TAKEDA PHARMACEUTICAL CO

Phase 1/2 Most advanced trial
TAK Developer
1 Registered trials

What is TAK-505?

TAK-505 is a bispecific T-cell engager that binds PD-L1 on tumor cells and the Vdelta1 segment of the gamma-delta T-cell receptor on gamma-delta T-cells. By bringing these cells together, it induces the cytotoxic activity of Vdelta1 gamma-delta T-cells against tumor cells. It is being studied in malignant solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
programmed death-ligand 1 (CD274), gamma-delta T-cell receptor Vdelta1 segment (TRDV1)
Mechanism
Immune activation, directed at programmed death-ligand 1 (CD274) and gamma-delta T-cell receptor Vdelta1 segment (TRDV1)
Pathways
T-cell mediated tumor cell killing, PD-1 mediated inhibition of T-cell expansion and survival
Therapy area
Oncology
Developer
TAKEDA PHARMACEUTICAL CO (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07436728 Phase 1/2 Malignant Solid Tumors Recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malignant Solid Tumors

Other drugs acting on CD274 / TRDV1

More from TAKEDA PHARMACEUTICAL CO

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind TAK-505

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.